KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Labcorp Holdings (LH) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Labcorp Holdings (LH) over the last 17 years, with Q3 2025 value amounting to $598.1 million.

  • Labcorp Holdings' Cash & Equivalents fell 6058.13% to $598.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $598.1 million, marking a year-over-year decrease of 6058.13%. This contributed to the annual value of $1.5 billion for FY2024, which is 18291.73% up from last year.
  • According to the latest figures from Q3 2025, Labcorp Holdings' Cash & Equivalents is $598.1 million, which was down 6058.13% from $647.3 million recorded in Q2 2025.
  • Over the past 5 years, Labcorp Holdings' Cash & Equivalents peaked at $2.0 billion during Q3 2021, and registered a low of $99.3 million during Q1 2024.
  • Its 5-year average for Cash & Equivalents is $1.0 billion, with a median of $727.9 million in 2023.
  • As far as peak fluctuations go, Labcorp Holdings' Cash & Equivalents skyrocketed by 48430.16% in 2021, and later plummeted by 8626.85% in 2024.
  • Over the past 5 years, Labcorp Holdings' Cash & Equivalents (Quarter) stood at $1.5 billion in 2021, then crashed by 78.23% to $320.6 million in 2022, then surged by 67.44% to $536.8 million in 2023, then surged by 182.92% to $1.5 billion in 2024, then tumbled by 60.62% to $598.1 million in 2025.
  • Its Cash & Equivalents was $598.1 million in Q3 2025, compared to $647.3 million in Q2 2025 and $369.4 million in Q1 2025.